Drug name - Byfavo
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9914738 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| US10472365 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| US9777007 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| US10342800 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(9 years from now) | |
| US10052334 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(9 years from now) | |
| US10195210 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(9 years from now) | |
| US9737547 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(9 years from now) | |
| US9827251 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(9 years from now) | |
| US10722522 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(9 years from now) | |
| US9561236 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Apr, 2033
(10 years from now) | |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.